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Abstract
Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with 
repetitive head impacts or exposure to blast waves. First described as punch-drunk syndrome and 
dementia pugilistica in retired boxers1–3, CTE has since been identified in former participants of 
other contact sports, ex-military personnel and following physical abuse4–7. No disease-
modifying therapies exist and diagnosis requires an autopsy. CTE is defined by an abundance of 
hyperphosphorylated tau protein in neurons, astrocytes and cell processes around blood vessels8,9. 
This, together with the accumulation of tau inclusions in cortical layers II and III, distinguishes 
CTE from Alzheimer’s disease and other tauopathies10,11. However, the morphologies of tau 
filaments in CTE and the mechanisms by which brain trauma can lead to their formation are 
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unknown. We used electron cryo-microscopy (cryo-EM) to determine the structures of tau 
filaments, with resolutions down to 2.3 Å, from the brains of three individuals with CTE, one 
American football player and two boxers. We show that filament structures are identical in the 
three cases, but distinct from those of Alzheimer’s and Pick’s diseases, and from those formed in 
vitro12–15. Like in Alzheimer's disease12,14,16–18, all six brain tau isoforms assemble into CTE 
filaments, and residues K274/S305-R379 form the ordered core of two identical C-shaped 
protofilaments. However, CTE filaments have novel protofilament interfaces, resulting in different 
overall morphologies. Moreover, a different conformation of the β-helix region creates a 
hydrophobic cavity that is absent in tau filaments from Alzheimer's disease brain. This cavity 
encloses an additional density that is not connected to tau, suggesting that incorporation of 
cofactors may play a role in tau aggregation in CTE. The tau filament structures presented here 
provide a unifying neuropathological criterion for CTE, and support the hypothesis that the 
formation and propagation of distinct conformers of assembled tau underlie different 
neurodegenerative diseases.
We extracted tau filaments from the temporal cortices of a former professional American 
football player (case 1) and two ex-professional boxers (cases 2 and 3) with 
neuropathologically-confirmed diagnoses of CTE. Perivascular hyperphosphorylated tau 
(AT8-positive) was present in neurons, astroglia and cell processes in the depths of cortical 
sulci and around blood vessels more generally, especially in the subependymal region 
(Figure 1a,b), with abundant tau inclusions composed of assembled, hyperphosphorylated 
three-repeat (3R) and four-repeat (4R) tau isoforms in superficial cortical layers (Figure 1c, 
Extended Data Figure 1 and see Methods).
Negative-stain electron microscopy revealed a predominant helical filament type in all three 
cases, comprising ~90% of filaments, with projected widths of 20-25 nm and cross-over 
spacings of 65-80 nm (Figure 1d; type I tau filaments). These filaments differed from paired 
helical and straight filaments (PHFs and SFs) of Alzheimer’s disease14,16, which consist of 
3R and 4R tau, narrow and wide Pick filaments (NPFs and WPFs) of Pick’s disease15, 
which are made of only 3R tau, and filaments assembled from either recombinant 3R or 4R 
tau using heparin17. The remaining filaments resembled PHFs, with pronounced helical 
twists resulting in projected widths of 15-30 nm (Figure 1d; type II tau filaments).
Immunoblotting of the sarkosyl-insoluble fractions from temporal cortex showed a pattern of 
tau bands like that of Alzheimer’s disease17,18 in the footballer and in both boxers16, 
consistent with the presence of all six brain tau isoforms in a hyperphosphorylated 
state17,18 (Extended Data Figure 1d). Immunogold negative-stain electron microscopy 
(immuno-EM) indicated that in all three CTE cases the sequences within the structured core 
of filaments contained R3 and R4 of tau, as in PHFs and SFs12,14, with the N-terminal parts 
of R1 and R2 forming part of an unstructured fuzzy coat (Extended Data Figure 2)19.
We used cryo-EM and helical reconstruction in RELION20 to determine the structures of 
the tau filaments of CTE (Figure 2, Extended Data Figure 3a, Extended Data Table 1). In all 
three cases, the predominant tau filament type, which we named type I, comprised pairs of 
identical protofilaments related by an approximate 21 helical symmetry (Figure 2a, Extended 
Data Figure 3a). The protofilament structure (CTE fold) is reminiscent of the C-shaped 
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Alzheimer fold12, but adopts a more open conformation. Most strikingly, additional density, 
not present in the Alzheimer fold, is surrounded by the density of the tau protein chain 
within the ordered core. Three-dimensional classification of the minority population of 
filaments from case 1 revealed that it comprised two types. About 75% of these filaments 
were composed of pairs of the same protofilament as in CTE type I tau filaments, including 
the extra density, but with a different protofilament interface, also related by an approximate 
21 helical symmetry (Figure 2b, Extended Data Figure 3a). We named these tau filaments 
CTE type II. The remaining filaments were identical to PHFs (Extended Data Figure 3b). 
For case 2, 3D classification only identified CTE type II tau filaments in the minority 
population (Figure 2b). For case 3, too few filaments were present to perform 3D 
classification or refinement of the minority population. As in PHFs and SFs14, we observed 
weaker densities extending from the N- and C-terminal regions of the core of all the filament 
types, as well as bordering the solvent-exposed side-chains of K317 and K321; H362 and 
K369; and K369 and K375. We conclude that over 97% of tau filaments in CTE comprise 
pairs of protofilaments with a conserved fold that is distinct from the Alzheimer and Pick 
folds.
By correcting for 3- and 4-fold astigmatism in the case 1 dataset (see Methods), we obtained 
a 2.3 Å-resolution map of CTE type I tau filaments (Figure 2c, Extended Data Figure 4). 
Densities corresponding to peptide group oxygen atoms, ordered solvent molecules and 
alternative conformations of amino acid side-chains were identified (Extended Data Figure 
5). Consequently, we could build and stereochemically refine an atomic model with 
unprecedented accuracy for amyloid filaments (Figure 2c). This revealed that, similar to the 
Alzheimer fold, the CTE fold is formed from residues K274 - R379 of 3R tau and S305 - 
R379 of 4R tau. The topology and secondary structure elements of the CTE fold are also 
similar to the Alzheimer fold12 (Figure 3a). These may be common features of filaments 
composed of both 3R and 4R tau in human brain. Eight β-strands (β1-8) pack against each 
other to form a combined cross-β/β-helix fold: β1 and β2 engage in anti-parallel cross-β 
packing against β8; β3 packs against β7; and β4-6 form a triangular β-helix that turns the 
main chain back on itself (Extended Data Figure 6). We resolved alternative conformations 
for the stretch of solvent-exposed side-chains in the β-helix (β4) with alternating positive 
and negative charges (Extended Data Figure 5c), demonstrating intramolecular charge 
interactions that compensate for stacked side-chains with identical charges, as hypothesised 
for the Alzheimer fold12. We also identified density corresponding to ordered solvent 
molecules, which we interpreted as water, between the backbone of V313 in β1 and the side-
chains of H374 and E372 of β8; between the side-chain of S320 and the backbones of K321 
of β2 and of G365; between the backbones of G333 and G335 and the side-chain of S356 in 
β7; and between the backbones of K337 and D348 in the β-helix (Extended Data Figure 5b). 
It is likely that other tau filament folds, including those of Alzheimer’s and Pick’s diseases, 
incorporate ordered solvent molecules in a similar manner.
The 3.4 Å-resolution map of the CTE type II tau filaments from case 1 also enabled us to 
generate a stereochemically refined atomic model (Figure 2d, Extended Data Figure 4). This 
showed that CTE type I and type II tau filaments are ultrastructural polymorphs, with a 
common protofilament structure, but different protofilament interfaces (Extended Data 
Figure 7). The protofilament interface of type I tau filaments consists of an anti-parallel 
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steric zipper formed by residues 324SLGNIH329. This interface is not compatible with 
phosphorylation of S324, which has been reported in Alzheimer’s disease21, and may 
explain why tau filaments with this protofilament interface are not observed in Alzheimer’s 
disease. The protofilament interface of CTE type II tau filaments is formed by the 
331KPGGGQVE338 motif that also forms the PHF interface in Alzheimer’s disease12,14. 
However, whereas the 322PGGG335 motif adopts an extended conformation in the Alzheimer 
fold, with all three glycine residues forming hydrogen bonds12, it has a kinked conformation 
in CTE type II filaments, with only G334 and G335 contributing to hydrogen bonding. 
Similar to PHFs14, the side-chain of K331 interacts with those of Q336 and E338 on the 
other protofilament. Possibly, a less stable interface accounts for the lower abundance of 
CTE type II than type I filaments.
A different β-strand packing in the β-helix motif creates a hydrophobic cavity that courses 
through CTE type I and II tau filaments (Figure 3a,b). In the Alzheimer fold, the interior 
facing side-chains of the β-helix pack tightly against each other, leaving no space to 
incorporate additional mass12. The distance between the Cα atoms of L344 and I354 is 11.5 
Å in the Alzheimer fold and 17 Å in the CTE fold (Figure 3c). This cavity is fully occupied 
by an extra density in the CTE fold (Figure 3d). The repacked β-helix coincides with the 
kink in the preceding 332PGGG335 motif, which is compensated for by a different 
conformation of the 353KIGSL357 motif than in the Alzheimer fold (Figure 3a). This new 
conformation, in which the side-chain of S356 points inward and that of L357 points 
outward, opposite to the Alzheimer fold, creates a tighter turn and precludes 
phosphorylation of S356. In addition, minor conformational adjustments tighten the turn 
formed by 341SEKL344 between β4 and β5 and relax the turn formed by 346FKDRV350 
between β5 and β6, compared to the Alzheimer fold. Overall, these conformational changes 
swivel the β-helix motif relative to the common cross-β packing stacks in the CTE fold, 
yielding a more open fold than in the tau filaments of Alzheimer’s disease.
The extra density in the cavity is as strong as that of tau, implying near-stoichiometric 
occupancies (Figure 2). It is surrounded by the hydrophobic side-chains of V339, L344, 
F346, V350 and I354, and the hydroxyl groups of S341 and S352, indicating that the extra 
density is primarily hydrophobic (Figure 3c,d). It does not connect to the density for the tau 
molecules, suggesting that it is not covalently linked to tau, and we found no evidence by 
mass-spectrometry of post-translational modifications of either S341 or S352. The extra 
density appears as an elliptical rod, with cross-sectional dimensions similar to those of the 
neighbouring side-chain of F346. Despite the resolution of our reconstruction, the extra 
density has few features along the helical axis and attempts to resolve it in this direction, by 
performing refinements with a larger helical rise, were unsuccessful. This is consistent with 
the observation that power spectra of individual filaments, as well as the average power 
spectra of all segments used for refinement, show only a layer line at 4.7 Å. The extra 
density may correspond to hydrophobic molecules that fill the cavity end-to-end, spanning a 
variable number of tau molecules along the helical axis. RNA and sulphated 
glycosaminoglycans, such as heparin, which induce tau aggregation in vitro22–24, are too 
hydrophilic and too large to occupy the cavity. Candidate molecules include non-polar 
sterols and sterol derivatives, as well as fatty acids and their derivatives, with one or two 
aliphatic chains.
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The CTE fold is, thus far, the only known amyloid structure to incorporate non-
proteinaceous molecules, suggesting a novel basis for conformer formation and propagation 
that is not only dependent on protein. Their buried nature, high occupancy and presence in 
the majority of filaments at end-stage disease indicate that these molecules are continuously 
incorporated during filament formation. They may act as cofactors to stabilise the folding of 
tau during initial filament assembly and/or subsequent seeded aggregation. Indeed, fatty 
acids induce recombinant tau to form filaments25 and CTE tau filaments seed the 
aggregation of 3R and 4R tau in cultured cells26. Moreover, in Niemann-Pick disease type 
C, cellular accumulation of cholesterol leads to the formation of abundant filamentous tau 
inclusions in brain27,28. In contrast, structures of in vitro assembled α-synuclein and β2-
microglobulin filaments contain similar cavities devoid of densities29–32. Sequestration of 
cellular factors by CTE filaments within the hydrophobic cavity may contribute to their 
neurotoxicity33.
The presence of tau inclusions around blood vessels in CTE suggests that cofactors for 
assembly may initially enter the brain from the periphery following head trauma, or be 
dependent on peripheral mechanisms. Repetitive head trauma has been shown to lead to a 
transient inflammatory response and compromise of the blood brain barrier34. Although the 
epidemiology of CTE is not known, it appears likely that brain trauma leads to CTE in only 
a subset of individuals, which could include those with elevated levels of cofactors35. The 
latter may, therefore, represent therapeutic targets for the prevention of tau assembly in CTE. 
Moreover, the stereochemical environment of cofactors within the CTE fold may inform the 
design of compounds that displace them, destabilise the filament fold or prevent the addition 
of tau monomers during filament elongation. Incorporation of a compound into a similar 
cavity in α-synuclein filaments has been shown to inhibit assembly36.
The CTE fold supports the hypothesis that conformers of filamentous tau define distinct 
tauopathies. We previously showed that tau filaments from Alzheimer's and Pick's diseases 
adopt different folds, establishing the existence of molecular conformers. In contrast to 
Pick’s disease, filaments in CTE have the same tau isoform composition as in Alzheimer's 
disease, showing that the same protein sequences can also form different conformers or 
aggregate strains. The results presented here provide a unifying neuropathological criterion, 
and confirm that dementia pugilistica and CTE are the same disease. The structures will aid 
in the design of specific tracer compounds, which are crucial for early diagnosis, so as to 
allow for timely therapeutic intervention.
Methods
Clinical history and neuropathology
Case 1 of CTE is a retired professional American football player, who died aged 67. Cases 2 
and 3 are former professional boxers, who died aged 67 and 78, respectively. Case 1 is 
documented for the first time, whereas cases 2 and 3 have been described before5,16,37–40. 
Case 1 played football during high school and college, and in over 30 professional matches 
during the 1970s. He reported a history of at least 30 concussions, 7 of which were 
accompanied by a loss of consciousness. Case 1 suffered from memory problems for several 
years and his family noticed an irritable mood and behavioural outbursts. He also reported 
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muscle weakness. He was able to walk a few steps, but was mostly reliant on a wheelchair. 
Physical examination confirmed a motor neuron-predominant weakness without prominent 
upper motor signs. The mother of case 1 was diagnosed with amyotrophic lateral sclerosis 
(ALS) in her 80s. During his footballing career, case 1 used the anabolic steroid 
methandrostenolone (Dianabol).
Neuropathologically, all three cases had stage 4 CTE5, with abundant silver-positive tau 
inclusions in brain (Figure 1a-c, Extended Data Figure 1a,b). By immunoblotting of the 
sarkosyl-insoluble fraction of the temporal cortex, a pattern consistent with the presence of 
all six brain tau isoforms was observed (Extended Data Figure 1d)16–18. Case 1 also had a 
small number of AT8-positive inclusions in spinal cord, mostly around blood vessels 
(Extended Data Figure 1c). TAR DNA-binding protein of 43 kDa (TDP-43) inclusions were 
present in spinal cord (Extended Data Figure 1e). TDP-43 inclusions and ALS are increased 
in individuals with CTE41,42. As described before5,16,37–39, case 2 had abundant tau and 
TDP-43 inclusions in both brain and spinal cord (Extended Data Figure 1a,c,f). The 
inclusions were present in separate cells (Extended Data Figure 1f, top right-hand panel). 
The TDP-43 pathology in brain was type B43. Dipeptide repeat inclusions (poly-GA) were 
present in cerebellum (Extended Data Figure 1f), prompting the sequencing of C9orf72. A 
heterozygous hexanucleotide GGGGCC repeat expansion mutation in intron 1 of C9orf72 
was detected (more than 145 repeats). Cases 1 and 3 had wild-type numbers of 
hexanucleotide repeats in both alleles. As mentioned before37, case 2 had a sibling with 
ALS. We conclude that case 2 suffered from inherited frontotemporal lobar degeneration 
(FTLD)/ALS, in addition to CTE. Case 3 had abundant tau inclusions in brain, as reported 
before16,40 (Extended Data Figure 1a). Abundant α-synuclein inclusions were also present 
in substantia nigra, dorsal motor nucleus of the vagus nerve, locus coeruleus and several 
other brain regions, confirming a previous study40 (Extended Data Figure 1g). This 
individual therefore had CTE and Parkinson’s disease. Clinical and neuropathological 
comorbidities are common in CTE44. The spinal cord of case 3 was not available, but there 
was no reported clinical or family history of ALS. By immunohistochemistry, abundant Aβ 
plaques were not observed in any of the three cases.
No known mutations in over 50 genes reported to cause Alzheimer’s disease, Parkinson’s 
disease, many cases of ALS or frontotemporal dementia were detected in the three cases by 
next-generation sequencing. The APOE genotypes were: Case 1 (ε2/ε3); case 2 (ε3/ε4); 
case 3 (ε3/ε3). Case 1 was homozygous, and cases 2 and 3 heterozygous for the 
TMEM106B variant, rs3173615 (c.554c>g, p.T185S), which has been reported to alter the 
neuropathology of CTE45. Case 1 was heterozygous and case 2 homozygous for the T allele 
at the RS5848 locus in the 3’-untranslated region of GRN. A C>T substitution occurs more 
frequently in cases of FTLD-TDP than in controls46.
Extraction of tau filaments
Sarkosyl-insoluble material was extracted from fresh-frozen temporal cortex, as 
described17. Approximately 6 g tissue was used for cryo-EM and 0.6 g for immuno-EM. 
The pelleted sarkosyl-insoluble material was resuspended in 10 mM Tris–HCl pH 7.4, 800 
mM NaCl, 5 mM EDTA, and 1 mM EGTA, with a final concentration of 10% (w/v) sucrose 
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at 750 μl/g, followed by centrifugation at 20,100g for 30 min at 4 °C. The resulting 
supernatants were centrifuged at 100,000g for 1 h at 4 °C. The pellets were resuspended in 
20 mM Tris–HCl pH 7.4 containing 100 mM NaCl at 250 μl/g and centrifuged at 100,000g 
for 30 min at 4 °C. The final pellets were resuspended in buffer at 15 μl/g for cryo-EM and 
150 μl/g for immuno-EM.
Electron cryo-microscopy
Extracted tau filaments were applied to glow-discharged holey carbon grids (Quantifoil Au 
R1.2/1.3, 300 mesh) and plunge-frozen in liquid ethane using an FEI Vitrobot Mark IV. 
Images were acquired on a Gatan K2-Summit detector in counting mode using an FEI Titan 
Krios at 300 kV. A GIF-quantum energy filter (Gatan) was used with a slit width of 20 eV to 
remove inelastically scattered electrons. Further details are given in Extended Data Table 1.
Helical reconstruction
Movie frames were corrected for gain reference, motion-corrected, and dose-weighted using 
MOTIONCOR247. Aligned, non-dose-weighted micrographs were used to estimate the 
contrast transfer function (CTF) in Gctf48. All subsequent image-processing steps were 
performed using helical reconstruction methods in RELION 3.020,49. Filaments were 
picked manually; CTE Type I tau filaments and PHF-like tau filaments were subsequently 
separated by reference-free 2D classification of segments comprising an entire helical 
crossover (using box sizes of 800 pixels and an inter-box distance of 14 Å). CTE Type I tau 
filament and PHF-like tau filament segments were re-extracted using box sizes of 270 pixels 
and an inter-box distance of 14 Å. Reference-free 2D classification was performed and 
segments contributing to suboptimal 2D class averages discarded. Initial 3D models were 
constructed de novo from 2D class averages from the case 1 dataset of segments comprising 
entire helical crossovers, and low-pass filtered to 40 Å.
For CTE type I tau filaments from case 1, 3D auto-refinement with optimisation of the 
helical twist was performed with a value of 10% for the helical z percentage parameter, 
before correcting for per-particle beam-induced motion and defoci using Bayesian polishing 
and CTF refinement, respectively. We then performed 3D classification with local 
optimisation of helical twist and rise, to remove segments contributing to suboptimal 3D 
class averages, and further 3D auto-refinement. Following attempted beam-tilt estimation, 
instead of the axial coma that would be produced by a tilted beam, we observed strong 3-
fold astigmatism in the per-Fourier-pixel average phase-error plot (Extended Data Figure 8, 
upper panels). Transmission electron microscopes often exhibit optical aberrations, i.e. 
unequal phase delays between the waves corresponding to different image frequencies. 
Those aberrations can always be separated into a symmetrical and an anti-symmetrical 
component: the symmetrical component gives rise to the CTF, while the anti-symmetrical 
component induces phase shifts in the complex amplitudes of the observed image. The 3-
fold astigmatism that we measured is such an anti-symmetrical aberration. In a development 
version of RELION, we modelled this using the first 6 anti-symmetrical Zernike 
polynomials (radial orders 1 and 2), assuming the effect to be constant across the entire data 
set. The coefficients of the Zernike polynomials were estimated so as to minimise the sum of 
squared per-pixel differences over all pixels and particles between the predicted and the 
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observed particle images. Expressing the aberration in this way allowed us to demodulate 
the phases of the particle images and thus to correct for the anti-symmetrical aberration, 
yielding an improvement in resolution from 2.7 to 2.5 Å. In addition to the anti-symmetrical 
aberration, we developed a related method to estimate the symmetrical aberrations. We 
extended the argument of the CTF sine function in RELION by an offset term that was 
modelled using the first 9 symmetrical Zernike polynomials (radial orders 0, 2 and 4). The 
coefficients were again estimated so as to minimise the sum of squared differences. 
Visualisation of the per-Fourier-pixel offset term revealed the presence of 4-fold 
astigmatism, which cannot be expressed by the traditional CTF model and which deforms 
the rings of the CTF from the usually elliptical shape to be slightly square-shaped (Extended 
Data Figure 8, lower panels). Correcting for 4-fold astigmatism, combined with a larger box 
size of 400 pixels, led to a resolution of 2.3 Å. Details of the higher-order aberration 
correction in RELION will be published elsewhere.
For CTE type I tau filaments from cases 2 and 3, 3D classification with local optimisation of 
helical twist and rise was performed to remove segments contributing to suboptimal 3D class 
averages, followed by 3D auto-refinement with optimisation of the helical twist with a value 
of 10% for the helical z percentage parameter. For the PHF-like tau filaments from case 1, 
CTE type II tau filaments were separated from PHFs by 3D classification with local 
optimisation of helical twist and rise. For case 2, 3D classification of the PHF-like tau 
filaments only identified CTE type II tau filaments. 3D auto-refinement with optimisation of 
the helical twist with a value of 10% for the helical z percentage parameter was then 
performed on the separated filaments. PHF-like tau filaments from case 3 did not yield 
reliable 3D reconstructions.
The final reconstructions were sharpened using the standard post-processing procedures in 
RELION and helical symmetry was imposed using the RELION helix toolbox20. Finally, 
overall resolution estimates were calculated from Fourier shell correlations at 0.143 between 
two independently refined half-maps, using phase randomization to correct for the 
convolution effects of a generous, soft-edged solvent mask50. Local resolution estimates 
were obtained using the same-phase randomization procedure, but with a soft spherical mask 
that was moved over the entire map. For further details, see Extended Data Table 1.
Model building and refinement
The two cross-β packing stacks and their linking regions were taken from the Alzheimer’s 
disease PHF model (PDB accession number 6HRE). The β-helix and its preceding and 
proceeding regions were built de novo into the 2.3 Å resolution reconstruction of CTE type I 
tau filaments from case 1 using COOT51. Water molecules and generic fused ring 
compounds (PubChem CID 1107) were added in COOT. The new model was then refined 
against the CTE type I and type II filament reconstructions from case 1 using targeted real-
space refinement in COOT. The models were subsequently translated to give stacks of three 
consecutive monomers to preserve nearest-neighbour interactions for the middle chains in 
subsequent Fourier space refinements in REFMAC52. Local symmetry restraints were 
imposed to keep all β-strand rungs identical. Side-chain clashes were detected using 
MOLPROBITY53 and corrected by iterative cycles of real-space refinements in COOT and 
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Fourier space refinements in REFMAC. Separate model refinements were performed against 
single half-maps, and the resulting models compared with the other half-maps to confirm the 
absence of overfitting. The final models were stable in refinements without additional 
restraints. Further details are given in Extended Data Table 1.
Immunolabelling, histology and silver staining
Immunogold negative-stain EM was carried out as described13. Primary antibodies were 
BR13613 (raised against tau residues 244–257), Anti-4R54 (raised against tau residues 275–
291, with D279; Cosmo Bio CAC-TIP-4RT-P01), BR13555 (raised against tau residues 
323–335), and TauC456 (raised against tau residues 354–369), all used at 1:50. Images were 
acquired at 11,000 ×, with a defocus value of -1.4 μm with a Gatan Orius SC200B CCD 
detector using a Tecnai G2 Spirit at 120 kV. To distinguish non-specific background from 
specific labelling, we only considered filaments with more than six gold beads to be 
positively labelled.
Immunoblotting was carried out as described13. Samples were resolved on 4-20% Tris-
glycine gels (Novex), and the primary antibodies were diluted in PBS plus 0.1% Tween 20 
and 1% bovine serum albumin (BSA). Primary antibodies were BR13355, used at 1:4,000, 
BR13613, used at 1:1,000, Anti-4R54 (Cosmo Bio CAC-TIP-4RT-P01), used at 1:2,000, 
BR13555, used at 1:4,000, and TauC456, used at 1:2,000, BR13455, used at 1:4,000, and 
AT8 (specific for pS202/pT205 tau; Thermo Fisher Scientific MN2010), used at 1:1,000.
Histology and immunohistochemistry were carried out as described57. Brain sections were 
8-μm thick and were counterstained with haematoxylin. Primary antibodies were AT8 
(Thermo Fisher Scientific MN1020), used at 1:300, AT100 (specific for pT212/pS214/
pT217 tau, Thermo Fisher Scientific MN1060), used at 1:400, Anti-4R54 (Cosmo Bio CAC-
TIP-4RT-P01), used at 1:400, RD3 (Merck 05-803), used at 1:3,000, anti-phospho-TDP-43 
(specific for pS409/pS410 TDP-43; Cosmo Bio CAC-TIP-PTD-M01), used at 1:1,000, 
SYN58 (specific for α-synuclein residues 119-137), used at 1:300, and anti-poly-GA 
(Cosmo Bio CAC-TIP-C9-P01), used at 1:300. Sections were silver-impregnated using the 
method of Gallyas-Braak to visualize inclusions59,60.
Whole-exome sequencing
Target enrichment made use of the SureSelectXT human all exon library (V6, 58 Mb, 
Agilent) and high-throughput sequencing was carried out using a HiSeq4000 (2 × 75 bp 
paired-end configuration, Illumina). Bioinformatics analyses were performed as 
described61.
Whole-genome sequencing
Sequencing libraries were prepared using 100 ng high-quality genomic DNA from 
cerebellum using the Illumina Nextera DNA Flex Library Prep Kit, and assessed using a 
Qubit and Agilent Bioanalyzer. High-throughput sequencing was carried out on multiple 
libraries pooled in equal molarity using a NovaSeq6000 (150 bp paired-end configuration, 
Illumina) and aligned to the human reference genome GRCh38 using BWA and Bwakit 
(v0.7.15). ExpansionHunter was applied to estimate expansion numbers of short tandem 
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repeats (v2.5.5) and germline variants were identified with Strelka2 (v2.9.9), with default 
parameters for whole genome sequence data. The variants were annotated for their effects 
with ANNOVAR62.
C9orf72 hexanucleotide repeat expansion
Repeat-primed polymerase chain reaction was used to determine the number of GGGGCC 
hexanucleotide repeats in the first intron of C9orf72 (Asuragen AmplideX PCR/CE C9orf72 
kit). Internal standards were analyzed along with samples to evaluate assay performance. Up 
to 25 repeats were determined with an accuracy of +/- 1 repeat and repeat numbers greater 
than 25 were determined with an accuracy of +/- 3 repeats.
Ethical review board and informed consent
The studies carried out at Indiana University and the University of Kansas were approved 
through the institutional review process at each University's. Informed consent was obtained 
from the patients’ next of kin.
Extended Data
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Extended Data Figure 1. Further characterization of tau pathologies in CTE cases 1-3. 
Coexisting pathologies.
a, Staining of tau inclusions in the temporal cortex of CTE cases 1, 2 and 3 using antibodies 
RD3 (3R tau), Anti-4R (4R tau) and AT8 (pS202/pT205 tau). Scale bar, 50 µm. b, Gallyas-
Braak silver staining of tau inclusions in the temporal cortex of CTE cases 2 and 3. Scale 
bar, 50 µm. c, Staining of tau inclusions in the spinal cord of CTE cases 1 and 2 using 
antibody AT8. Scale bar, 50 µm. d, Immunoblots of sarkosyl-insoluble tau from the temporal 
cortices of CTE cases 1, 2 and 3 using antibodies BR133, BR134 and AT8. e, Staining of a 
TDP-43 inclusion in the spinal cord of CTE case 1. Scale bar, 25 µm. f, Staining of CTE 
case 2 for poly-GA inclusions in the cerebellum and TDP-43 inclusions in the spinal cord, 
temporal cortex, hippocampus and amygdala. In the top right-hand panel, double-labelling 
of tau inclusions (AT8; brown) and TDP-43 inclusions (red) is shown. Scale bars, 25 µm 
(upper panels) and 50 µm (lower panels). g, Staining of CTE case 3 for α-synuclein 
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inclusions in the substantia nigra, dorsal motor nucleus (DMN) of the vagus nerve and locus 
coeruleus. Scale bar, 50 µm. Nuclei were counterstained blue in all images.
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Extended Data Figure 2. Immunolabelling of tau filaments extracted from the brains of CTE 
cases 1-3.
a,b, Immunoblots and immunolabelling of tau filaments extracted from the temporal cortices 
of CTE cases 1, 2 and 3. a, Immunoblots of sarkosyl-insoluble tau using antibodies BR136, 
Anti-4R, BR135 and TauC4. b, Representative immuno-EM images of tau filaments labelled 
with antibodies BR136 and Anti-4R. Unlike BR136 and Anti-4R, antibodies BR135 and 
TauC4 did not label the filaments, indicating that their epitopes lie within the ordered 
filament cores. Scale bar, 200 nm.
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Extended Data Figure 3. Cryo-EM two-dimensional and three-dimensional classification.
a, 2D-class averages spanning an entire helical crossover of type I and type II tau filaments 
from CTE cases 1-3. b, Cryo-EM structure of PHFs from the temporal cortex of CTE case 1.
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Extended Data Figure 4. Cryo-EM map and model comparisons.
a,b, Fourier shell correlation curves between two independently refined half-maps (bold 
black line); between the final cryo-EM reconstruction and refined atomic model (bold red 
line); between the first half-map and the atomic model refined against the first half map 
(brown line); and between the second half map and the atomic model refined against the first 
half map (blue dashed line) for CTE type I (a) and type II (b) filaments. c,d, Local resolution 
estimates for the CTE type I (c) and type II (d) filament reconstructions. e,f, Views normal to 
the helical axis of the CTE type I (e) and type II (f) filament reconstructions.
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Extended Data Figure 5. Cryo-EM map of type I tau filaments from CTE case 1.
a-c, Close-up view of the cryo-EM map with the atomic model overlaid showing densities 
for oxygens atoms of the peptide groups (a) and ordered solvent molecules (b). c, Side-chain 
conformations for the alternating positively and negatively charged solvent-exposed side-
chains of residues 336-343 in successive rungs.
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Extended Data Figure 6. CTE tau filament fold.
a, Schematic view of the CTE tau filament fold. b, Rendered view of the secondary structure 
elements in the CTE fold, depicted as three successive rungs. c, As in b, but in a view 
perpendicular to the helical axis, revealing the changes in height within a single molecule.
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Extended Data Figure 7. Comparison of CTE type I and type II tau filament folds and 
protofilament interfaces.
a, The type I protofilament structure is shown in purple and the type II protofilament 
structure in gold. b, As in a, but showing backbone atoms only. c,d, Packing between 
residues 322CGSLGNIH329 of the two protofilaments in type I filaments (c) and between 
residues 331KPGGGQVE338 of the two protofilaments in type II filaments (d).
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Extended Data Figure 8. Measurement and modelling of optical aberrations.
Three-fold astigmatism (antisymmetrical; upper panels) and 4-fold astigmatism 
(symmetrical; lower panels) measured in per-Fourier-pixel average phase-error plots (left 
images) and represented by our parametric model (right images) for CTE type I tau 
filaments from case 1. The plot shows image frequencies up to 2.9 Å. The outlier ring at 4.7 
Å corresponds to the dominant frequency given by a double-repetition of the helix. This ring 
has been excluded from the parametric fit.
Extended Data Table 1
Cryo-EM data collection, refinement and validation 
statistics.
Case 1
(EMD-0527,
EMD-0528)
Case 2 Case 3
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Data collection and processing
Magnification xl30,000 xl05,000 X130,000
Voltage (kV) 300 300 300
Electron exposure (e−/Å2) 55.5 55 57.5
Defocus range (μm) -1.7 to -2.8 -1.7 to -2.8 -1.7 to-2.8
Pixel size (Å) 1.055 1.15 1.05
Symmetry imposed 21 helical 21 helical 21 helical
Initial no. particle images 203,154 148,485 31,889
Final no. particle images Type I: 113,178 Type I: 14,147 Type I: 14,959
Type II: 7,621 Type II: 3,080
PHF: 3,199
Map resolution (Å; FSC=0.143) Type I: 2.3 Type I: 3.7 Type I: 3.45
Type II: 3.4 Type II: 7.6
PHF: 7.5
Helical rise (Å) 2.37 2.37 2.37
Helical twist (°) 179.4 179.4 179.4
Case 1 Type I Case 1 Type II
(6NWP) (6NWQ)
Refinement
Initial model used (PDB code) 6HRE 6HRE
Model resolution (Å; FSC=0.5) 2.32 3.45
Map sharpening B factor (Å2) -50 -50
Model composition
    Non-hydrogen atoms 3738 3738
    Protein residues 480 480
Protein B factor (Å2) 51.7 115
R.m.s. deviations
    Bond lengths (Å) 0.01 0.01
    Bond angles (°) 1.27 0.81
 Validation
    MolProbity score 1.53 1.75
    Clashscore 6.74 3.27
    Poor rotamers (%) 1.39 1.52
 Ramachandran plot
    Favored (%) 94.44 90.91
    Allowed (%) 100 100
    Disallowed (%) 0 0
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Filamentous tau pathology of CTE.
a, Perivascular staining of tau inclusions in the depth of a sulcus (S) in the frontal cortex of 
CTE case 1 using antibody AT8 (pS202/pT205 tau; brown). Nuclei were counterstained 
blue. Scale bar, 100 µm. b, Perivascular staining of tau inclusions in the subependymal 
regions of CTE cases 1, 2 and 3 using antibody AT8 (brown). Nuclei were counterstained 
blue. Scale bar, 100 µm. c, Staining of tau inclusions using antibody AT100 (pT212/pS214/
pT217 tau; brown) and Gallyas-Braak silver staining (black) of inclusions in the temporal 
cortex of CTE case 1. Nuclei were counterstained blue. Scale bar, 50 µm. d, Negative-stain 
electron micrographs of a type I and a type II tau filament extracted from temporal cortex of 
CTE case 1. Scale bar, 50 nm.
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Figure 2. Cryo-EM structures of CTE type I and type II tau filaments.
a,b, Cryo-EM structures of CTE type I tau filaments from the temporal cortices of cases 1, 2 
and 3 (a) and type II tau filaments from the temporal cortices of cases 1 and 2 (b). All 
structures show identical pairs of protofilaments and the same inter-protofilament packing 
between cases in CTE type I and type II filaments. c,d, Sharpened, high-resolution cryo-EM 
maps of CTE type I (c) and type II (d) tau filaments with their corresponding atomic models 
overlaid. Unsharpened, 4.5 Å low-pass filtered maps are shown as grey outlines, showing 
weaker densities extending from the N- and C-terminal regions, as well as bordering the 
solvent-exposed side-chains of K317 and K321, H362 and K369, and K369 and K375.
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Figure 3. Comparison of the CTE and Alzheimer tau filament folds.
a, Schematic of the secondary structure elements in the CTE and Alzheimer folds, depicted 
as a single rung. The positions of S356 (green ‘S’) and L357 (white ‘L’) in the two folds are 
highlighted. The extra density is depicted in grey. b, Overlay of the CTE fold (purple) and 
the Alzheimer fold (grey), shown as a single rung. c, The β-helices of the Alzheimer fold 
(grey) and the CTE fold (purple), depicted as a single rung. The distances between the Cα 
atoms of L344 and I354 are shown as orange dashed lines. d, View normal to the helical axis 
of the CTE fold β-helix, depicted as three rungs and shown as a cross-section through S341 
and S352.
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